Superluminal Medicines, a Boston-based biotech startup, has raised $60 million in Series B funding to advance its AI-driven obesity drug into clinical trials by the end of 2026. The round was led by BVF Partners, with participation from notable investors including NVIDIA and Eli Lilly.
TL;DR
- Superluminal Medicines raises $60M Series B to fund clinical trials for a rare genetic obesity drug by the end of 2026.
- The financing syndicate includes BVF Partners, Deep Track Capital, Perceptive Advisors, and existing investors like NVIDIA and Eli Lilly.
- The company's AI-driven platform targets GPCRs, aiming to develop selective, biased MC4R agonists for obesity and potential future applications in metabolic diseases.
What happened
Superluminal Medicines announced the closing of a $60 million Series B financing on September 3, 2026. The round was led by BVF Partners, with new investors Deep Track Capital and Perceptive Advisors joining existing backers like RA Capital Management, Insight Partners, NVIDIA, and Eli Lilly. The company described the round as oversubscribed, indicating strong investor interest.
Proceeds from the financing will support the initiation of a Phase 1 clinical trial for a selective, biased MC4R agonist targeting rare genetic forms of obesity by the end of 2026. The trial aims to address conditions like Bardet-Biedl syndrome (BBS) and hypothalamic obesity, which currently have limited treatment options.
Superluminal's AI-driven platform integrates advanced structural biology with proprietary machine learning tools to accelerate the discovery of candidate-ready small molecules. The platform focuses on GPCRs, leveraging Agentic Cryo-EM capabilities and GPCR-focused co-folding models to generate differentiated small molecule medicines.
Why it matters
The $60 million Series B funding enables Superluminal to transition from a discovery platform company to a clinical-stage biotechnology company. This milestone is significant for the AI-driven drug discovery sector, demonstrating the potential of machine learning in developing targeted therapies for rare diseases.
For investors and startups, this funding round highlights the growing interest in AI-driven biotech solutions. The participation of major players like NVIDIA and Eli Lilly underscores the competitive advantage of integrating AI and machine learning into drug discovery processes.
The competitive angle lies in Superluminal's ability to target historically challenging GPCRs with its AI-driven platform. The company's approach aims to maximize therapeutic activity while minimizing side effects, potentially offering a novel treatment option for patients with rare genetic forms of obesity and future applications in broader metabolic diseases.
Key facts
- Superluminal Medicines raised $60 million in Series B funding on September 3, 2026.
- The round was led by BVF Partners, with new investors Deep Track Capital and Perceptive Advisors joining existing backers like NVIDIA and Eli Lilly.
- Proceeds will support a Phase 1 clinical trial for a selective, biased MC4R agonist by the end of 2026.
- The trial targets rare genetic forms of obesity, including Bardet-Biedl syndrome (BBS) and hypothalamic obesity.
- Superluminal's AI-driven platform integrates advanced structural biology with proprietary machine learning tools.
- The company's platform focuses on GPCRs, leveraging Agentic Cryo-EM capabilities and GPCR-focused co-folding models.
- Superluminal previously raised $120 million in Series A funding on September 9, 2024, led by RA Capital Management.
- The company has a strategic collaboration with Eli Lilly, with potential milestone payments and royalties up to $1.3 billion.
Context
Superluminal Medicines is part of a growing trend of biotech startups leveraging AI and machine learning to accelerate drug discovery. The company's focus on GPCRs, which are involved in a wide range of physiological processes, positions it at the forefront of developing targeted therapies for complex diseases.
The successful Series B funding round reflects the increasing confidence of investors in AI-driven biotech solutions. The participation of major pharmaceutical companies like Eli Lilly and technology giants like NVIDIA highlights the interdisciplinary collaboration driving innovation in the sector.
As AI continues to transform drug discovery, startups like Superluminal Medicines are poised to make significant contributions to the development of novel therapies. The company's progress from a discovery platform to a clinical-stage biotechnology company exemplifies the potential of AI in addressing unmet medical needs and improving patient outcomes.
